Ventripoint Expands Subscription Access for FDA-Cleared AI Cardiac Imaging

Ventripoint is expanding subscription-based access to its FDA-cleared AI-powered cardiac imaging platform VMS+ 4.0, enabling hospitals to adopt advanced 3D heart ultrasound imaging without upfront capital purchases. The platform enhances cardiac care by providing MRI-comparable volumetric measurements and is gaining traction through clinical studies and partnerships in North America and Europe.

This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it.